Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nadofaragene firadenovec versus observation in intermediate-risk non-muscle invasive bladder cancer
2024-512029-10-00Phase 3Authorised
- Sponsor
- Ferring Pharmaceuticals
- Start
- Dec 2025
- Modality
- Gene Therapies
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial in non-muscle-invasive bladder cancer (NMIBC) comparing ADSTILADRIN with Observation / standard of care (2 arms). Primary endpoint: Recurrence-free survival. Planned start Dec 2025; status: authorised.
02
Drugs
nadofaragene firadenovec
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on 2024-512029-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512029-10-00.